FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
14/11/2022
Voltar para busca
Dado oficial do USPTO
VETTER-JECT
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
VETTER-JECT
ST13
US500000079250207Classe
5, 10, 39, 42
Pedido
79250207
Registro
6791709
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
51
Atualização mais recente
14/11/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 10, 39, 42
Data de depósito
24/09/2018
Data de registro
19/07/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/07/2022
Última transação
19/07/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
13
Localização do titular
DE
Examinador
AGREDA, SAMANTHA
Unidade examinadora
N50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Vetter Pharma-Fertigung GmbH & Co. KG
Representantes
M. Scott Alprin Alprin Law Offices, P.C.
Classificação técnica
Classes Nice
Classe 5Classe 10Classe 39Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations and medicines for the treatment of infectionscancerdepressionheart diseasevascular diseaseintestinal disorderlung and bronchial disfunctionliver disfunctioninflammation and inflammatory diseasesoral and laryngeal diseaseoptical and cranial disordersarthritismigrainemucopolysaccharidosishaemophiliamultiple sclerosisosteoporosisneuronal disordersdiabeteserectile disfunctioninfertilitycrohn's diseasehereditary angioedemathrombosisencephalitisdiseases of the thyroid or parathyroid glandsmetabolic diseasesmuscular atrophydisturbance of growth and anemia; pharmaceutical solutions for oral administration in the nature of sterile aseptic solutionsnamely in the form of tabletspillscapsulesdropsmedical juice and medical syrupall for the treatment of infectionscancerdepressionheart diseasevascular diseaseintestinal disorderlung and bronchial disfunctionliver disfunctioninflammation and inflammatory diseasesoral and laryngeal diseaseoptical and cranial disordersarthritismigrainemucopolysaccharidosishaemophiliamultiple sclerosisosteoporosisneuronal disordersdiabeteserectile disfunctioninfertilitycrohn's diseasehereditary angioedemathrombosisencephalitisdiseases of the thyroid or parathyroid glandsmetabolic diseasesmuscular atrophydisturbance of growth and anemia; injectable pharmaceuticals in the nature of antibody solutionsbiologicalspeptidespolypeptidesproteinsenzymesnucleic acidscoagulation factorsinterferonsphosphonates and bisphosphonatesgrowth factorshormoneshormoneantagonistsinsulinheparinslow molecular heparins and sulfur hexafluorideall for the treatment of infectionscancerdepressionheart diseasevascular diseaseintestinal disorderlung and bronchial disfunctionliver disfunctioninflammation and inflammatory diseasesoral and laryngeal diseaseoptical and cranial disordersarthritismigrainemucopolysaccharidosishaemophiliamultiple sclerosisosteoporosisneuronal disordersdiabeteserectile disfunctioninfertilitycrohn's diseasehereditary angioedemathrombosisencephalitisdiseases of the thyroid or parathyroid glandsmetabolic diseasesmuscular atrophydisturbance of growth and anemia; eyedropscontact lens solutions; medicated compresses; medical plastersmaterials for dressings in the nature of bandageswadding and gauze; filled medical injection devicesin particular syringes and instruments for injectionsinjectorsauto-injectors and single-chamber and dual-chamber disposable syringesall sold filled with pharmaceutical preparations for the treatment of infectionscancerdepressionheart diseasevascular diseaseintestinal disorderlung and bronchial disfunctionliver disfunction inflammation and inflammatory diseasesoral and laryngeal diseaseoptical and cranial disordersarthritismigrainemucopolysaccharidosishaemophiliamultiple sclerosisosteoporosisneuronal disordersdiabeteserectile disfunctioninfertilitycrohn's diseasehereditary angioedemathrombosisencephalitisdiseases of the thyroid or parathyroid glandsmetabolic diseasesmuscular atrophydisturbance of growth and anemia
Classe 10
Empty medical injection devicesin particular syringes and instruments for injectionsinjectorsauto-injectors and single-chamber and dual-chamber disposable syringesall sold empty; medicine containers for administering medicinesof glass and/or plastic in the nature of medical syringesinjectorsauto-injectorsdisposable syringes and disposable cannulae; syringe holders being containers specially adapted for holding medical syringes; medical syringesdisposable syringesdisposable cannulae sold either individually or in combinationall for medical purposes
Classe 39
Bottling servicesbottling of liquid and solid substancesin particular of pharmaceuticalsmedicines and solutions
Classe 42
Development of syringes and instruments for injectionsinjectors and packaging for the aforesaid goods; laboratory tests in the nature of scientific testing in the fields of chemicalphysics and process engineering; product development and conducting of scientific tests in the fields of pharmacological and microbiological processes
Publicações
Histórico de despachos e eventos da marca no USPTO.
51 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
22/10/2022
FIMP
FINAL DISPOSITION PROCESSED
22/10/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
19/10/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
19/07/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
19/07/2022
GPNX
NOTIFICATION PROCESSED BY IB
09/05/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/05/2022
PUBO
PUBLISHED FOR OPPOSITION
03/05/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/04/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
13/04/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/04/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/03/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/03/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/03/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
25/03/2022
GNS1
NOTIFICATION OF SUBSEQUENT FINAL EMAILED
27/09/2021
GNCF
CONTINUATION OF FINAL REFUSAL E-MAILED
27/09/2021
CNCF
ACTION CONTINUING A FINAL - COMPLETED
27/09/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
28/07/2021
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
16/05/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
28/04/2021
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
28/04/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
02/10/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
12/03/2020
GNSL
LETTER OF SUSPENSION E-MAILED
12/03/2020
CNSL
SUSPENSION LETTER WRITTEN
12/03/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/03/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/03/2020
ALIE
ASSIGNED TO LIE
10/03/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
05/03/2020
GNSL
LETTER OF SUSPENSION E-MAILED
05/03/2020
CNSL
SUSPENSION LETTER WRITTEN
05/03/2020
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
04/03/2020
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
06/12/2019
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
29/11/2019
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
05/09/2019
GNFR
FINAL REFUSAL E-MAILED
05/09/2019
CNFR
FINAL REFUSAL WRITTEN
05/09/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/08/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/08/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/08/2019
RFNT
REFUSAL PROCESSED BY IB
02/03/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
13/02/2019
RFRR
REFUSAL PROCESSED BY MPU
12/02/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/02/2019
CNRT
NON-FINAL ACTION WRITTEN
04/02/2019
MAFR
APPLICATION FILING RECEIPT MAILED
01/02/2019
DOCK
ASSIGNED TO EXAMINER
28/01/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
28/01/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
24/01/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VETTER-JECT ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.